Savara Inc.
SVRA
$0.07
Change (1 day)
$5.70
Year High
$2.82
Year Low
Categories
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
P/S ratio for Savara Inc. (SVRA)
P/S ratio as of 2023: 0.00
According to Savara Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Savara Inc. from 2000 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | 0.00 |
| 2021 | 0.00 |
| 2020 | 265.39 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 50.82 |
| 2015 | 1262604.94 |
| 2014 | 44283.19 |
| 2013 | 0.00 |
| 2012 | 0.00 |
| 2011 | 0.00 |
| 2010 | 70.36 |
| 2009 | 136.09 |
| 2008 | 13.54 |
| 2007 | 80.92 |
| 2006 | 0.00 |
| 2005 | 395.60 |
| 2004 | 0.00 |
| 2003 | 0.00 |
| 2002 | 0.00 |
| 2001 | 0.00 |
| 2000 | 0.00 |